NCT07874269Not yet recruiting
MSC Secretome and rTMS for Motor Recovery After Subacute Ischemic Stroke
Effectiveness of Combined Mesenchymal Stem Cell Secretome and Repetitive Transcranial Magnetic Stimulation on Motor Recovery and Quantitative Electroencephalography Biomarkers in Patients With Subacute Ischemic Stroke: A Double-Blind Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 21 Oct 2026
Brief summary (registry, in English)
This randomized, double-blind, controlled clinical trial evaluates the effectiveness and safety of combined mesenchymal stem cell (MSC) secretome and repetitive transcranial magnetic stimulation (rTMS) for motor recovery in patients with subacute ischemic stroke. Participants will be randomized to either an intervention group receiving intravenous MSC secretome combined with high-frequency ipsilesional rTMS or a control group receiving placebo infusion and sham rTMS. The intervention is administered once weekly for 8 weeks. The primary outcome is change in motor function measured using the Fugl-Meyer Motor Scale. Secondary outcomes include changes in quantitative electroencephalography biomarkers, including sensorimotor rhythm, delta-theta-to-alpha-beta ratio, and beta coherence, as well as spasticity assessed using the Modified Ashworth Scale and treatment-related adverse events.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 205 (estimated)
- First submitted
- 8 Oct 2026
- Start date
- Nov 2026
- Primary completion date
- Jul 2027
- Lead sponsor
- Jumraini Tammasse
- Diseases
- Stroke
- NCT number
- NCT07874269
What you commit to
- Study type: Interventional
- Planned participants: 205
- From Nov 2026 to the primary completion date, Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of active seizures.
- Severe systemic disease that may affect participant safety or interfere with study participation.
Other
- Presence of intracranial metal or implanted devices that are contraindications to rTMS.
Who the study is looking for
- Age 30 to 75 years.
- Diagnosis of subacute ischemic stroke, 1 to 6 months after stroke onset.
- First-ever ischemic stroke.
- Ischemic stroke confirmed by magnetic resonance imaging (MRI) or computed tomography (CT).
- Able to undergo repetitive transcranial magnetic stimulation (rTMS) therapy.
Age in the registry: 30 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Inggit Medical Centre Coordinator of this site? Confirm its status | Makassar | Indonesia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.